Early-stage study reveals strong immune response and safety profile for ACI-35.030 More: AC Immune’s Tau-targeting therapy shows promise in early Alzheimer’s trial Source: News
read moreBased in Poland, biologics-focused CDMO Rezon Bio announced its launch on the European contracting scene Monday. The company plans to use its biosimilars know-how to make development and commercialization processes simple and straightforward for partners. More: New CDMO on the
read moreThe results, coupled with a prior win, could set up Enhertu to be a “foundational treatment option” in the curative-intent breast cancer setting, AstraZeneca and Daiichi Sankyo said. More: AZ, Daiichi's Enhertu shows early breast cancer prowess with another trial
read moreKedrion Biopharma has scored an FDA approval for Qivigy, a treatment for adults with primary humoral immunodeficiency (PI). Along with the nod, the Italian company announced plans to boost its investment in the United States. More: Italian plasma specialist Kedrion
read moreIn laying out their respective plans Monday to launch new direct-to-patient platforms paring down the prices of popular medicines in the U.S., Novartis and Boehringer Ingelheim are falling in line with demands from President Donald Trump and joining the likes
read moreIn a bid to “harmonize its share listing structure,” AstraZeneca aims to list its shares directly on the New York Stock Exchange. While AZ will continue to trade on the London Stock Exchange and retain its U.K. headquarters, the move
read more© 1994 - 2026 B.M. Pharmaceuticals